Melanoma & Skin Cancer | Specialty

Adjuvant Treatment Selection in High-Risk Melanoma

June 17th 2014

Adjuvant Therapy for Stage III Melanoma

June 17th 2014

Role of Adjuvant Radiation Therapy in Melanoma

June 17th 2014

Molecular Testing in Resectable Melanoma

June 17th 2014

Lymph Node Management in Melanoma

June 17th 2014

Imaging and SLN Biopsy for Patients With Melanoma

June 17th 2014

Introduction: Surgical Excision of Melanoma

June 17th 2014

Checkpoint Agents Are Shifting Paradigms Toward Immunotherapy

June 16th 2014

The concept of manipulating the immune system to treat cancer has experienced waxing and waning levels of enthusiasm over decades of clinical investigation.

Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma

June 10th 2014

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Dr. Wolchok on Ipilimumab After Complete Resection of Stage III Melanoma

June 5th 2014

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, Giant of Cancer Care, discusses the initial efficacy and safety results from the EORTC 18071 phase III trial, which looked at ipilimumab versus placebo after complete resection of stage III melanoma.

Follow-up of Concurrent Immunotherapies Shows Unprecedented Survival Rate in Melanoma

June 3rd 2014

Long-term follow-up results demonstrated nearly doubled median OS with the combination of ipilimumab and nivolumab compared with either agent alone.

T-VEC Combinations, Monotherapy Intriguing in Unresectable Melanoma

June 2nd 2014

The intratumoral injection talimogene laherparepvec demonstrated promise in combinations and utility as a monotherapy in certain subsets of patients with unresectable melanoma.

New Study Findings Confirm Pembrolizumab's Durable Responses in Metastatic Melanoma

June 2nd 2014

The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.

Adjuvant Ipilimumab Reduces Risk of Recurrence in Stage III Melanoma

June 2nd 2014

The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.

Dr. Andtbacka Discusses OS With T-VEC in Melanoma

June 2nd 2014

Robert H. I. Andtbacka, MD, CM, from the Huntsman Cancer Institute, discusses OS findings from the phase III OPTiM study that explored T-VEC in patients with unresectable melanoma.

Dr. Fong Discusses Intratumoral Electroporation of Plasmid IL-12 in Melanoma

June 2nd 2014

Lawrence Fong, MD, from the University of California, San Francisco, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.

Rare Skin Cancer on Palms and Soles More Likely to Come Back Compared to Other Melanomas

May 29th 2014

Study raises concern about surgical "margins" for acral melanoma tumors, known to target the darker skins of Asians, African-Americans and Hispanics

Dr. Pavlick on a Phase II Trial of Cyclophosphamide and Ipilimumab in Melanoma

May 28th 2014

Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.

Dr. Luke Discusses the Phase III COMBI-d Trial Results

May 24th 2014

Jason J. Luke, MD, instructor, Department of Medicine, Harvard School of Medicine, staff physician, medical oncologist- melanoma, Dana-Farber Cancer Institute, discusses the controversy behind the COMBI-d trial results.